Neurogene Reaches 52-Week High on $200M Private Placement

Dow Jones

2024-11-05

By Josh Beckerman

Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million.

The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year.

The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.

Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital.

Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 04, 2024 13:31 ET (18:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481530830"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481530830\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481530830?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 02:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481530830","market":"fut","top_or_hot":-1,"title":"Neurogene Reaches 52-Week High on $200M Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million. \n</p>\n<p>\n  The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year. \n</p>\n<p>\n  The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026. \n</p>\n<p>\n  Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital. \n</p>\n<p>\n  Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 13:31 ET (18:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurogene Reaches 52-Week High on $200M Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurogene Reaches 52-Week High on $200M Private Placement\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-11-05 02:31</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million. \n</p>\n<p>\n  The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year. \n</p>\n<p>\n  The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026. \n</p>\n<p>\n  Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital. \n</p>\n<p>\n  Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 04, 2024 13:31 ET (18:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGNE","symbol_name":"NEUROGENE INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2481530830","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481530830","pubTimestamp":1730745060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million.The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year.The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026.Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital.Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NGNE":"NEUROGENE INC","BK4139":"生物科技"},"translate_title":"Neurogene私募2亿美元股价创52周新高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million. \n\n\n  The stock was up 44% to $66.55 on Monday, with an intraday high of $73.59. Shares are up about 243% this year. \n\n\n  The company expects the proceeds, combined with existing cash and cash equivalents, will provide runway into the second half of 2027. In August, the company said it expected current cash, cash equivalents and marketable securities to fund operations into the second half of 2026. \n\n\n  Participants in the financing include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital and Samsara BioCapital. \n\n\n  Neurogene it will host a Nov. 11 webcast to present interim data from its Phase 1/2 trial of NGN-401 for Rett syndrome. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 13:31 ET (18:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}